Shaowen Tang Selected Research

Antitubercular Agents

5/2022	The relationship between relative telomere length and anti-tuberculosis drug-induced hepatitis : A case-control study.
12/2020	NR1I2 genetic polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity: A systematic review and meta-analysis.
1/2020	Association between NR1I2 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population: A case-control study.
1/2019	Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population.
6/2015	Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
1/2015	Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study.
1/2013	Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort.
9/2012	NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
1/2011	Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shaowen Tang Research Topics

Disease

10	Drug-Related Side Effects and Adverse Reactions 05/2022 - 09/2012
9	Tuberculosis (Tuberculoses) 05/2022 - 01/2011
5	Liver Diseases (Liver Disease) 08/2022 - 03/2015
5	Chemical and Drug Induced Liver Injury 08/2020 - 01/2013
4	Hemorrhage 01/2022 - 05/2015
3	Hepatitis 05/2022 - 01/2013
2	Chronic Renal Insufficiency 02/2022 - 12/2021
2	Inflammation (Inflammations) 01/2022 - 12/2021
1	Hepatitis A (Hepatitis, Infectious) 05/2022
1	Obesity 05/2022
1	Overweight 05/2022
1	Calciphylaxis 01/2022
1	Venous Thromboembolism 01/2022
1	Ulcer 01/2022
1	Rare Diseases (Rare Disease) 01/2022
1	Hypoxia (Hypoxemia) 12/2021
1	COVID-19 11/2020
1	Hemolysis 08/2020
1	Secondary Hyperparathyroidism 11/2019
1	Atherosclerosis 01/2019
1	Heart Failure 01/2019
1	Cardiac Arrhythmias (Arrythmia) 01/2019
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2019
1	Atrial Fibrillation 01/2017
1	Ischemic Stroke 07/2015
1	Carcinoma (Carcinomatosis) 05/2015
1	Chronic Obstructive Pulmonary Disease (COPD) 03/2015
1	Pulmonary Hypertension 03/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2014
1	Pulmonary Tuberculosis 06/2014
1	Hypercalcemia (Milk Alkali Syndrome) 01/2013
1	Hypophosphatemia 01/2013
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2013
1	Hyperphosphatemia 01/2013

Drug/Important Bio-Agent (IBA)

9	Antitubercular AgentsIBA 05/2022 - 01/2011
5	Pharmaceutical PreparationsIBA 10/2021 - 01/2013
3	ORALIT (ORS)IBA 08/2022 - 01/2020
2	AnticoagulantsIBA 01/2022 - 01/2017
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2019 - 08/2019
2	EnzymesIBA 03/2015 - 01/2013
1	Fish OilsIBA 01/2022
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021
1	Platelet-Derived Growth FactorIBA 12/2021
1	Retinaldehyde (Retinal)IBA 12/2021
1	Messenger RNA (mRNA)IBA 12/2021
1	CytokinesIBA 12/2021
1	Small Interfering RNA (siRNA)IBA 12/2021
1	Angiopoietin-2IBA 12/2021
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 12/2021
1	qingfei paidu decoctionIBA 11/2020
1	Rifampin (Rifampicin)FDA LinkGeneric 08/2020
1	Heme (Haem)IBA 08/2020
1	AntibodiesIBA 08/2020
1	ABO Blood-Group SystemIBA 08/2020
1	Phosphotransferases (Kinase)IBA 01/2019
1	Warfarin (Coumadin)FDA LinkGeneric 05/2018
1	Apolipoproteins E (ApoE)IBA 05/2018
1	Vitamin K FDA Link 01/2017
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2017
1	RivaroxabanIBA 01/2017
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2017
1	Oral ContraceptivesIBA 07/2015
1	Ethinyl Estradiol (Estinyl)FDA LinkGeneric 07/2015
1	Estrogens (Estrogen)FDA Link 07/2015
1	Progestins (Progestagens)IBA 07/2015
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 03/2015
1	Sildenafil Citrate (Viagra)FDA Link 03/2015
1	Interleukin-6 (Interleukin 6)IBA 01/2015
1	AntigensIBA 08/2014
1	Interferon-gamma (Interferon, gamma)IBA 06/2014
1	Cytochrome P-450 CYP2E1 (CYP2E1)IBA 01/2013
1	lanthanum carbonate (Fosrenol)FDA Link 01/2013
1	Phosphates (Orthophosphate)IBA 01/2013
1	CalciumIBA 01/2013

Therapy/Procedure

5	Therapeutics 01/2022 - 01/2013
3	Parathyroidectomy 02/2022 - 11/2019
1	Prenatal Care (Care, Prenatal) 05/2022
1	Intramuscular Injections 01/2022
1	Renal Dialysis (Hemodialysis) 01/2022
1	Cardiopulmonary Resuscitation (CPR) 01/2019
1	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2019
1	Percutaneous Coronary Intervention 01/2017
1	Length of Stay 05/2015
1	Esophagectomy 05/2015